Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05849389 · ClinicalTrials.gov registry record · Phase 2
Vosoritide for Short Stature in Turner Syndrome
A Phase 2 study of Turner Syndrome and Short Stature, sponsored by Roopa Kanakatti Shankar, MBBS, MS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05849389 is a Phase 2 study of Turner Syndrome and Short Stature that is actively recruiting participants, run by Roopa Kanakatti Shankar, MBBS, MS. The registered enrollment target is 20 participants, below the 518-participant average among 14 other Turner Syndrome trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05849389, a Phase 2 study of Turner Syndrome and Short Stature, is actively recruiting participants, sponsored by Roopa Kanakatti Shankar, MBBS, MS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Turner syndrome (TS) is characterized by a missing whole or part of the second sex chromosome in a phenotypic female, resulting in short stature due to haploinsufficiency of the short-stature homeobox-containing (SHOX) gene. Growth hormone (GH) is an approved therapy for this condition, although not associated with GH deficiency, and benefits are modest. Vosoritide, a C-type natriuretic peptide (CNP) analog, targets chondrocytes within the growth plate leading to increased cell proliferation and hypertrophy. We hypothesize that patients with TS and short stature will respond to vosoritide treatment leading to increased growth velocity. This study will enroll pre-pubertal girls with TS who are either naïve to GH or have had a poor response to GH therapy. All subjects will be treated with vosoritide for 12 months and will be assessed for safety monitoring and improvement in height outcomes. Annualized growth velocity (AGV) on vosoritide will be compared to AGV in the 6-18 months prior to initiation of vosoritide based on historical data available in the medical record. Subjects with a positive response to therapy will be given the option to continue in the extension phase of the study during which they will continue to receive vosoritide until growth cessation.
Conditions Studied
Interventions
- DRUG Vosoritide
Study Locations (1)
District of Columbia
- Children's National Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-04-12 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05849389
The ClinicalTrials.gov registry entry for NCT05849389 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 518-participant average among 14 other Turner Syndrome trials with a reported enrollment target (96% lower). The listed sponsor is Roopa Kanakatti Shankar, MBBS, MS, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Turner Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Vosoritide is the first listed.
NCT05849389 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05849389 about?
NCT05849389 is a clinical study titled "Vosoritide for Short Stature in Turner Syndrome". Turner syndrome (TS) is characterized by a missing whole or part of the second sex chromosome in a phenotypic female, resulting in short stature due to haploinsufficiency of the short-stature homeobox-containing (SHOX) gene. Growth hormone (GH) is an approved therapy for this condition, although not...
What is the current status of trial NCT05849389?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-04-12. Estimated completion is 2026-09.
What conditions does trial NCT05849389 study?
This clinical trial studies the following conditions: Turner Syndrome, Short Stature.
What interventions are being tested in trial NCT05849389?
The interventions under investigation include: Vosoritide (DRUG).
Who is sponsoring clinical trial NCT05849389?
This trial is sponsored by Roopa Kanakatti Shankar, MBBS, MS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05849389 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Turner Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
RECRUITING · Phase 2
-
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Natural History of Noncirrhotic Portal Hypertension
RECRUITING
-
UTHealth Turner Syndrome Research Registry
RECRUITING
-
Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome
RECRUITING · Phase 4
-
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.